TSX Venture:
QPT
EDMONTON, AB, June 9, 2023
/CNW/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the
"Company") provided the following corporate update today.
Grant of Stock Options
Quest announces the granting of 1,250,000 stock options to 2
Officers, at an exercise price of $0.10 per common share, expiring 5 years from the
date of grant, subject to TSX Venture Exchange approval.
About Quest PharmaTech
Inc.
Quest PharmaTech Inc is a publicly traded, Canadian based
biopharmaceutical company (TSX-V: QPT) developing products to
improve the quality of life. The company has a 42.5% ownership
interest in OncoQuest Inc. which sold its immunotherapy technology
assets to Korea-based OQP Bio Inc. in 2020. Quest also has a 23%
ownership interest in OncoVent, a Chinese joint venture developing
antibody-based immunotherapeutic products for cancer for the
Greater China territory. Quest is
also developing proprietary MAb AR 9.6 targeting truncated MUC16 as
theranostic agents for cancer. AR 9.6 was licensed from
University of Nebraska and currently is
in late preclinical stage. To learn more, visit
www.questpharmatech.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Quest PharmaTech Inc.
